1. Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Drug Saf. 1995; 12:348–357.
2. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs. 2000; 59:323–389.
3. Thiruvengadam NR, Forde KA, Chandrasekhara V, et al. Tacrolimus and indomethacin are safe and effective at reducing pancreatitis after endoscopic retrograde cholangiopancreatography in patients who have undergone liver transplantation. Clin Gastroenterol Hepatol. 2020; 18:1224–1232.
4. Thiruvengadam NR, Kochman ML. Emerging therapies to prevent post-ERCP pancreatitis. Curr Gastroenterol Rep. 2020; 22:59.
5. Jin S, Orabi AI, Le T, et al. Exposure to radiocontrast agents induces pancreatic inflammation by activation of nuclear factor-κB, calcium signaling, and calcineurin. Gastroenterology. 2015; 149:753–764.
6. Orabi AI, Wen L, Javed TA, et al. Targeted inhibition of pancreatic acinar cell calcineurin is a novel strategy to prevent post-ERCP pancreatitis. Cell Mol Gastroenterol Hepatol. 2017; 3:119–128.
7. Oh HC, Easler JJ, El Hajj II, et al. Effect of calcineurin inhibitor on post-endoscopic retrograde cholangiopancreatography pancreatitis in patients with liver transplantation: a propensity-matched cohort study. Korean J Intern Med. 2020; 35:1364–1370.
8. Wang R, Wang W, Ma K, et al. Variation in tacrolimus trough concentrations in liver transplant patients undergoing endoscopic retrograde cholangiopancreatography: a retrospective, observational study. Front Pharmacol. 2020; 11:1252.
9. Rao HB, Vincent PK, Nair P, et al. Preventive effect of tacrolimus on patients with post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Endosc. 2022; 55:665–673.
10. Testoni PA, Mariani A, Aabakken L, et al. Papillary cannulation and sphincterotomy techniques at ERCP: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2016; 48:657–683.